<DOC>
	<DOCNO>NCT00367744</DOCNO>
	<brief_summary>The purpose study examine effect rosiglitazone limb fat mitochondrial index HIV-1-infected subject receive stable antiretroviral therapy contain stavudine ( d4T ) zidovudine ( AZT ) .</brief_summary>
	<brief_title>Rosiglitazone Effect Mitochondria Lipoatrophy</brief_title>
	<detailed_description>This phase II , randomize , double-blind , placebo-controlled study rosiglitazone treatment HIV-associated lipoatrophy . Subjects receive blind study treatment 48 week . This study examine effect rosiglitazone limb fat mitochondrial index HIV-1-infected subject receive stable antiretroviral therapy contain d4T AZT . The study also assess safety tolerability rosiglitazone population , effect carotid IMT , prevalence metabolic syndrome , lipid parameter glucose metabolism .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lipodystrophy</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>Lipoatrophy Thymidine spar ARV least 24 week Prior thymidine NRTIs least 12 month Diabetes Heart failure Liver disease Hormonal therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2006</verification_date>
	<keyword>mitochondrion</keyword>
	<keyword>HIV</keyword>
	<keyword>lipoatrophy</keyword>
</DOC>